{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:41:30Z","timestamp":1783395690009,"version":"3.54.6"},"reference-count":14,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,1]]},"abstract":"ABSTRACT<\/jats:title>\n \n mecA<\/jats:italic>\n -positive\n Staphylococcus aureus<\/jats:named-content>\n isolates phenotypically susceptible to cefoxitin (\n mecA<\/jats:italic>\n -methicillin-sensitive\n S. aureus<\/jats:named-content>\n [MSSA]) have been identified. We describe the treatment and outcomes among patients with\n mecA<\/jats:italic>\n -MSSA bloodstream infections (BSI) and MRSA BSI matched 1:1 for age, BSI origin, and BSI type (\n n<\/jats:italic>\n = 17 per group). Compared to MRSA BSI patients,\n mecA<\/jats:italic>\n -MSSA BSI patients more often experienced clinical failure (58.8% and 11.8%,\n P<\/jats:italic>\n = 0.010), driven largely by persistent bacteremia (35.3% and 11.8%).\n mecA<\/jats:italic>\n -MSSA BSI patients may be at higher risk for poor clinical outcomes.\n <\/jats:p>","DOI":"10.1128\/aac.01396-17","type":"journal-article","created":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T00:55:24Z","timestamp":1508201724000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":5,"title":["A Retrospective Analysis of Treatment and Clinical Outcomes among Patients with Methicillin-Susceptible Staphylococcus aureus Bloodstream Isolates Possessing Detectable\n mecA<\/i>\n by a Commercial PCR Assay Compared to Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Isolates"],"prefix":"10.1128","volume":"62","author":[{"given":"Dylan","family":"Jones","sequence":"first","affiliation":[{"name":"Ascension, Wheaton Franciscan-St. Francis Campus, Department of Pharmacy, Milwaukee, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy H.","family":"Elshaboury","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Department of Pharmacy, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Munson","sequence":"additional","affiliation":[{"name":"Marquette University, Milwaukee, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Dilworth","sequence":"additional","affiliation":[{"name":"Aurora St. Luke's Medical Center, Department of Pharmacy Services, Milwaukee, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv512"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.05022-11"},{"key":"e_1_3_2_4_2","volume-title":"CLSI document M100S","author":"CLSI","year":"2017","unstructured":"CLSI. 2017. Performance standards for antimicrobial susceptibility testing; approved standard, 27th ed. CLSI document M100S. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"27"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02463-09"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq146"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/313753"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053783"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/524667"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-8-585"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.11.1275"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000296"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02727-16"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.11.3070-3075.2001"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01564-12"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01396-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01396-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:12:20Z","timestamp":1645477940000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01396-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1128\/AAC.01396-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.01396-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"2017-07-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01396-17"}}